Our first product HTPEP-001, a TGF-β activation inhibitor by targeting TSP-1, has two administration routes: intravenous drip and aerosol inhalation. Previous data shows promise as a potentially effective anti-fibrotic agent available for the treatment of Idiopathic Pulmonary Fibrosis and that is without adverse systemic side effects of TGF-β inhibition or side effects of blocking physiological fibrosis.

With the achievement of a significant milestone of HTPEP-001, we will also develop another TGF-β program named HTPEP-002 available for the treatment of fibrotic-related cancer, such as Colon Cancer, Pancreatic Cancer, Liver Cancer and so on.